Вы искали: outcome (Датский - Английский)

interview outcome
interview outcome

tabel 3 - outcome-hændelser i plato
table 3 -outcome events in plato

measurement of metabolic outcome of carbohydrates of two types of cereal products
measurement of metabolic outcome of carbohydrates of two types of cereal products,

when the selection is completed , you will be informed by email of the outcome .
when the selection is completed , you will be informed by email of the outcome .

retten erkender, at der er et komplekstforhold melleminput ogresultater(outcome)iderevideredefinansieringsaftaler.
the court recognises that the relationship between aidinputs and results(outcomes)in the audited financing agreementsis a complex one. thisis discussedinfurther detailin annex iii.

ingen af disse analyser var tilstrækkeligt store til at kunne detektere forskelle i outcome hos poor metabolisers.
none of these analyses were adequately sized to detect differences in outcome in poor metabolisers.

ingen af disse analyser var tilstrækkeligt store til at kunne detektere forskelle i outcome hos personer med poor metabolisme.
none of these analyses were adequately sized to detect differences in outcome in poor metabolisers.

ingen af disse analyser var tilstrækkeligt store til at kunne detektere forskelle i outcome hos personer med ringe metabolisme.
none of these analyses were adequately sized to detect differences in outcome in poor metabolisers.

ikommissionensretningslinjerforforvaltningaf projektforløb (marts 2004), skelnes der mellem outputindikatorer og outcome- og effektindikatorer.
the commission’s project cycle management guidelines(march 2004) distinguishbetweenoutputindicators,ontheonehand,and outcomeandimpactindicators, onthe other.

der er ingen afsluttede outcome undersøgelser, som vurderer den kardiovaskulære langtidseffekt hos patienter, som får rosiglitazon i kombination med metformin.
12 there are no studies completed assessing long-term cardiovascular outcome in patients receiving rosiglitazone in combination with metformin.

i skotland blev drug outcome research study (doris), som gennemføres af university of glasgow, påbegyndt i 2001.
in scotland, the drug outcome research study (doris), being carried out by the university of glasgow, started in 2001.

i et outcome forsøg med patienter med betydende makrovaskulær sygdom var hyppighedenaf alvorlig hjerteinsufficiens ved kombinationsbehandling med insulin 1,6% højere med pioglitazon end med placebo.
in an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.

i et outcome forsøg med patienter med betydende macrovaskulær sygdom var hyppigheden af alvorlig hjerteinsufficiens ved kombinationsbehandling med insulin 1, 6% højere med pioglitazon end med placebo.
in an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.

livskvaliteten blev vurderet i en undergruppe af patienter i griphon-studiet på baggrund af spørgeskemaet camphor (cambridge pulmonary hypertension outcome review).
quality of life was assessed in a subset of patients in the griphon study using the cambridge pulmonary hypertension outcome review (camphor) questionnaire.

hensigten er, at de stoffer, der udvælges, bør være dem med "highest expected regulatory outcome" (heros).
the intent is that those selected should be those with the ‘highest expected regulatory outcome’ (heros).

at læger opfordres til at inkludere patienter i opfølgningsprogrammet, transthyretin amyloidosis outcome survey (thaos) og at de får oplysninger om, hvordan patienter inkluderes i dette internationale sygdomsregister.
that physicians are encouraged to enter patients in the transthyretin amyloidosis outcome survey (thaos) and provided with details how to enroll patients into this international disease registry

trial outcome index-resultater understøttede fact-l- og lcs-resultaterne. a værdier for iressa versus carboplatin/paclitaxel.
trial outcome index results were supportive of fact-l and lcs results a values presented are for iressa versus carboplatin/paclitaxel.

i proactive, et kardiovaskulært outcome- forsøg, blev 5238 patienter med type 2- diabetes mellitus og betydende makrovaskulær sygdom randomiseret til pioglitazon eller placebo i tillæg til eksisterende antidiabetika og kardiovaskulær behandling i op til 3, 5 år.
in proactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.